Biocon Biologics Limited, a subsidiary of Biocon Ltd., has secured full and exclusive global rights for its biosimilar Adalimumab (Hulio®) from Fujifilm Kyowa Kirin Biologics Co., Ltd. (FKB). This expanded agreement supersedes the prior collaboration, granting Biocon Biologics end-to-end responsibility for manufacturing, commercialization, and further development. Under the new terms, FKB will be compensated through a technology license fee and royalties on sales, while also contributing to the offset of certain development costs incurred by Biocon Biologics. Commercial production is slated to begin after successful technology transfer and regulatory approvals. Shreehas Tambe, CEO & Managing Director of Biocon Biologics, stated that this strategic move enhances flexibility and cost efficiency, reinforcing the company's commitment to making high-quality biologics more accessible for patients with inflammatory diseases worldwide. Biocon Biologics initially acquired commercial rights to biosimilar Adalimumab in 2022 through its acquisition of Viatris’ global biosimilars business.